FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

10 letters match. Newest first.

  1. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk
  2. Amazing Meds

    FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.

    High risk
  3. GLP-1 Solution

    GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.

    High risk
  4. EA WORKS Limited Liability Company dba Trust Labs

    FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.

    High risk
  5. Meds For Vets, LLC

    Meds For Vets compounded unapproved animal drugs from bulk substances and failed manufacturing quality rules, including sterility controls.

    High risk
  6. Boothwyn Pharmacy LLC

    FDA warns Boothwyn Pharmacy over unapproved compounded animal drugs and falsified endotoxin records.

    High risk
  7. ProRx, LLC

    FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.

    High risk
  8. Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy

    FDA warns Drug Depot dba APS Pharmacy over compounded drugs made with ineligible bulk substances.

    Medium
  9. Imprimis Rx LLC

    FDA warns Imprimis Rx over false, misleading promotion of compounded eye drug Pred-Moxi-Brom.

    Low
  10. Pharmaceutical Care Solutions dba Pharmacy Solutions

    FDA warns Pharmaceutical Care Solutions dba Pharmacy Solutions over compounded drugs made with ineligible bulk substances and lacking FDA approval.

    Medium